Add-On Radioligand Therapy Slows Metastatic Hormone-Sensitive Prostate Cancer

By News Health
5 hours Ago

(MedPage Today) — BERLIN — Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression with the addition of radioligand therapy to hormonal treatment, a large randomized trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118061

Author :

Publish date : 2025-10-21 15:49:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Immunizing Both Mom and Baby Against RSV Appears Effective, Safe

Obesity Driving Chronic Conditions in Young People

GLP-1 Drugs Tied to Lower Risk of Legal Blindness in People With Diabetes

Alzheimer's Paper Retracted; Smartphone App Helps Migraine; Alcohol and Alzheimer's

Food Allergy Rates Fall After 2015 Peanut Feeding Advice

OTC CGM at Walmart; California's Own Insulin; Ozempic's Price Negotiations Underway